Business
Arius to present at BioFinance conference in Toronto on May 3, 2006
Arius to present at BioFinance conference in Toronto on May 3, 2006.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nTORONTO, May 2 /CNW/ - ARIUS Research Inc. (\"ARIUS\") (TSX-V: ARI),\nannounced that Dr. David Young, Chairman, President and Chief Scientific\nOfficer will present an update on the company at the BioFinance conference in\nToronto. Dr. Young's presentation is scheduled for May 3, 2006 at 9:00 a.m.\nEST at the Toronto Marriott Hotel.\n\nAbout ARIUS Research\nARIUS Research Inc. is a biotechnology company dedicated to personalizing\ncancer therapy through the discovery and development of novel anticancer\nmonoclonal antibodies (MAbs). Established in 1999, ARIUS has built a\nproprietary technology platform, FunctionFIRST(TM), that rapidly identifies\npowerful MAbs targeting a variety of cancer indications. This antibody\ngeneration engine has enabled ARIUS to assemble a growing pipeline, which is\nused for commercial collaborations and in-house development. ARIUS has ongoing\npartnerships with key biotechnology and drug development companies. The\ncompany is listed on the TSX Venture Exchange under the symbol \"ARI\".\n\nThe TSX Venture Exchange has not reviewed and does not accept\nresponsibility for the adequacy or accuracy of this statement.\n\nForward-Looking Statement Certain statements in this news release\nconstitute \"forward-looking statements\" within the meaning of the Private\nSecurities Litigation Reform Act of 1995, which involve known and unknown\nrisks, uncertainties and other factors that may cause our actual results to be\nmaterially different from any future results, performance or achievements\nexpressed or implied by such statements. Forward-looking statements in this\nrelease include, but are not limited to, ARIUS successfully advancing its new\nproduct programs as well as licensing opportunities. These statements are only\npredictions and actual events or results may differ materially. Factors that\ncould cause such actual events or results expressed or implied by such forward-\nlooking statements to differ materially from any future results expressed or\nimplied by such statements include, but are not limited to: early stage of\ndevelopment; technology and product development; dependence on and management\nof current and future corporate collaborations; future capital needs;\nuncertainty of additional funding; no assurance of market acceptance;\ndependence on proprietary technology and uncertainty ...